Table 1. HIV-1 assay results from Participant A longitudinal pre-ATI blood and tissue sampling.
| Lab/ Location | Days Post-ART | Sample Type | Assay Type | Result | Sample Volume Tested or LOD |
|---|---|---|---|---|---|
| UCSF | 22 | PBMC | HIV RNA/DNA | 3.2 RNA c/106 CD4 + T cells; DNA neg |
2.8 DNA copies/106 cells |
| UCSF | 47 | Rectum/GALT | HIV RNA/DNA | Neg | 16.6 (DNA), 25.4 (RNA) copies/million cells |
| UCSF & U. Montreal | 55 | PBMC (sorted)1 | HIV RNA/DNA | Neg | CD4+ T cell subsets (LODs 0.5 to 37.2 copies/million cells) |
| U. Montreal | 55 | PBMC | TILDA | Neg | 736,000 CD4+ T cells |
| Hopkins (Siliciano) | 166 | PBMC | qVOA | Neg | 40 million resting CD4+ T cells |
| UCSF | 288, 301, 316, 756, 1034 | PBMC | HIV RNA/DNA | Neg | 0.7 to 4.6 DNA or RNA copies/million CD4+ T cell |
| Pittsburgh | 301 | PBMC | Total Inducible Virus Recovery | Neg | 25 million CD4+ T cells |
| Pittsburgh | 301 | Plasma | Plasma iSCA | Neg | 29 mL (<0.06 copies/mL) |
| Pittsburgh | 301 | PBMC | HIV DNA | Neg | 4.4 million CD4+ T cells |
| UCSD | 301 | PBMC | ddPCR for HIV genomic DNA and 2LTR circles | Neg | 2.4 copies/million cells |
| UCSF | 316 HIV-1 D | Bone Marrow (sorted)2 | HIV RNA/DNA | Neg | Total, CD4+ T cells, myeloid cells, HSPC: 0.2–97.5 copies/million cells |
| UCSF | 316 | CSF | HIV RNA | Neg | <40 copies/mL |
| CSF Cell Pellet | HIV RNA/DNA | Neg | 457 (DNA) 68 (RNA) copies/million cells | ||
| UCSF | 350 | Lymph Node (inguinal, sorted)1 | HIV RNA/DNA | Neg | 0.8 to 28.2 copies/million CD4+ T cell immune subset |
| UCSF | 357 | Rectum (colonoscopy) | HIV RNA/DNA | Neg | 0.9 (DNA), 6.9 (RNA) copies/million CD4+ T cells |
| UCSF | 357 | Ileum (colonoscopy) | HIV RNA/DNA | Neg | 1.9 (DNA), 4.1 (RNA) copies/million cells |
| Hopkins (Blankson) | 545 | PBMC | mVOA | 1/10 mice viremic (201 c/mL plasma)3 | 530 million CD4+ T cells |
| Hopkins (Siliciano) | 756 | PBMC | Whole genome sequencing | Neg | 15 million resting CD4+ T cells |
1 DNA and RNA obtained from sorted CD4+ T cell immune subsets (TN, TCM, TEM, and TTM).
2 DNA and RNA obtained from sorted CD4+ T cells, common lymphoid progenitor cells, hematopoietic stem/progenitor cells, and myeloid cells.
3 Unable to verify result.
Abbreviations: ART, antiretroviral therapy; ATI, analytical treatment interruption; c/mL, copies/mL; CSF, cerebrospinal fluid; ddPCR, droplet digital PCR; GALT, gut-associated lymphoid tissue; HSPC, hematopoietic stem and progenitor cells; iSCA, integrase single copy assay; LOD, limit of detection; LTR, long-terminal repeat; Neg, negative; PBMC, peripheral blood mononuclear cell; qVOA, quantitative viral outgrowth assay; TILDA, Tat/Rev Induced Limiting Dilution Assay; UCSD, University of California San Diego; UCSF, University of California San Francisco; VOA, viral outgrowth assay.